Welcome to our dedicated page for Celanese Del news (Ticker: CE), a resource for investors and traders seeking the latest updates and insights on Celanese Del stock.
Celanese Corporation produces chemistry and specialty material solutions through businesses that include the Acetyl Chain and Engineered Materials. Company updates commonly cover acetyl-chain pricing and supply actions for acetic acid, vinyl acetate monomer, acetyl derivatives, dispersions, EVA, solvents, and related products, along with engineered-materials developments in specialty polymers used across automotive, electronics, medical, building, and consumer markets.
Celanese news also includes earnings releases, dividend declarations, manufacturing-footprint actions, nylon and POM production updates, carbon capture and utilization applications in binders for airlaid nonwovens, and board governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Celanese Corporation (NYSE: CE) has announced a quarterly cash dividend of $0.70 per share on its common stock. This dividend will be payable on May 15, 2023, to stockholders of record as of May 1, 2023. Celanese is a global leader in specialty materials and chemical production, with a workforce of approximately 13,000 employees worldwide and reported net sales of $9.7 billion in 2022. The company utilizes its extensive chemistry and technology expertise to create value across various industries and consumer applications.
Celanese Corporation (NYSE: CE) has announced a conference call to discuss its first quarter 2023 results on May 10, 2023, at 10:00 a.m. Eastern time. The earnings press release will be distributed after market close on May 9, 2023. Investors can access the call via webcast or by phone, with a dial-in number of 1-877-407-0989 for domestic participants. A replay will be available from May 10 to May 24, 2023. Celanese reported net sales of $9.7 billion in 2022 and continues to strengthen its position as a leader in the chemical industry.
Celanese (NYSE: CE) has announced a partnership with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for the iDose® TR intraocular implant. This device aims to lower intraocular pressure in patients with glaucoma by providing continuous, long-duration therapy, addressing issues of patient non-adherence to topical medications. Glaukos submitted a New Drug Application for iDose TR in February 2023, pending FDA approval. The collaboration is aimed at enhancing patient treatment options in ophthalmology, leveraging the proven performance of Celanese's VitalDose technology, which has a solid history of controlled-release applications.
Celanese Corporation (NYSE: CE) has announced a collaboration with Alessa Therapeutics to develop a new oncology drug using Alessa's sustained localized drug delivery technology. The partnership aims to enhance treatment for oncology patients by reducing systemic side effects.
According to Alessa's Vice President, the collaboration has facilitated the rapid development of their drug candidate, with plans to advance to human studies later this year. Celanese emphasized its commitment to improving therapeutic outcomes through innovative drug delivery solutions.
Celanese Corporation (NYSE: CE), a leader in specialty materials, announced price hikes for Hytrel® TPC resins, set to take effect on March 15, 2023. The increases include 0.45 EUR/kg in the EMEA region and 0.5 USD/kg in both Asia Pacific and the Americas. Individual grades may experience greater hikes as per contract terms. Celanese, headquartered in Dallas, reported $9.7 billion in net sales for 2022 and employs around 13,000 people globally.